Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Carboplatin/pemetrexed should be ‘a standard option’ in elderly NSCLC patients
Key clinical point: Chemotherapy with carboplatin and pemetrexed plus pemetrexed maintenance was noninferior to docetaxel monotherapy in patients age 75 years and older with non–small cell lung cancer.
Major finding: The median overall survival was 15.5 months in the docetaxel arm and 18.7 months in the carboplatin/pemetrexed arm (stratified hazard ratio, 0.850; P for noninferiority = .003).
Study details: A phase 3, randomized trial of 433 patients age 75 years and older with non–small cell lung cancer.
Disclosures: The study was funded by agencies of the Japanese government. The investigators disclosed relationships with Boehringer Ingelheim, AstraZeneca, Eli Lilly Japan KK, and many other companies.
Okamoto I et al. JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2019.6828.